Deina Walsh - Bone Biologics Chief Officer
| BBLG Stock | USD 0.82 0 0.24% |
Executive
Ms. Deina H. Walsh serves as Chief Financial Officer of Bone Biologics Corporationrationration. She is a certified public accountant and ownerfounder of DHW CPA, PLLC a Public Companies Accounting Oversight Board registered firm since 2014. Prior to forming her firm, Ms. Walsh has 13 years at a public accounting firm where as a partner she was actively responsible for leading firm audit engagements of publicly held entities in accordance with PCAOB standards and compliance with SEC regulations, including internal control requirements under section 404 of the SarbanesOxley Act. Ms. Walsh had a global client base including entities throughout the United States, Canada and China. These entities encompass a diverse range of industries including manufacturing, wholesale, life sciences, pharmaceuticals, and technology. Her experience includes work with startup companies and wellestablished operating entities. She has assisted many entities seeking debt and equity capital. Areas of specialty include mergers, acquisitions, reverse mergers, consolidations, complex equity structures, foreign currency translations and revenue recognition complexities since 2015.
| Age | 60 |
| Tenure | 10 years |
| Address | 2 Burlington Woods Drive, Burlington, MA, United States, 01803 |
| Phone | 781 552 4452 |
| Web | https://www.bonebiologics.com |
Deina Walsh Latest Insider Activity
Tracking and analyzing the buying and selling activities of Deina Walsh against Bone Biologics stock is an integral part of due diligence when investing in Bone Biologics. Deina Walsh insider activity provides valuable insight into whether Bone Biologics is net buyers or sellers over its current business cycle. Note, Bone Biologics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bone Biologics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Deina Walsh over six months ago Acquisition by Deina Walsh of 11104 shares of Bone Biologics subject to Rule 16b-3 | ||
Deina Walsh over a year ago Acquisition by Deina Walsh of 12500 shares of Bone Biologics at 3.61 subject to Rule 16b-3 | ||
Deina Walsh over a year ago Bone Biologics exotic insider transaction detected | ||
Deina Walsh over a year ago Purchase by Deina Walsh of 8000 shares of Bone Biologics |
Bone Biologics Management Efficiency
The company has return on total asset (ROA) of (0.694) % which means that it has lost $0.694 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2871) %, meaning that it created substantial loss on money invested by shareholders. Bone Biologics' management efficiency ratios could be used to measure how well Bone Biologics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.99. The Bone Biologics' current Return On Capital Employed is estimated to increase to -1.15. At this time, Bone Biologics' Debt To Assets are most likely to increase significantly in the upcoming years.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ryan McSeveney | Bluejay Diagnostics | N/A | |
| Michael Marcroft | SINTX Technologies | N/A | |
| Paul Wotta | Nuwellis | 67 | |
| Amir Rippel | NanoVibronix | N/A | |
| Ryan Bock | SINTX Technologies | N/A | |
| David OBrien | SINTX Technologies | 59 | |
| John Kowalczyk | Nuwellis | N/A | |
| FACC MBA | Nuwellis | N/A | |
| Indranil Dey | Bluejay Diagnostics | 62 | |
| Sean Wirtjes | Rapid Micro Biosystems | 55 | |
| Michael Wysocki | Rapid Micro Biosystems | N/A | |
| Kristine Williams | Rapid Micro Biosystems | N/A | |
| Al Diaz | ReShape Lifesciences | N/A | |
| John Ballard | Vivos Therapeutics | N/A | |
| Lindsey Harrison | NanoVibronix | N/A | |
| Vitaliy Epshteyn | Nuwellis | 46 | |
| Stephen CPA | NanoVibronix | 69 | |
| Robert Scott | Nuwellis | 44 | |
| Les DeLuca | Bluejay Diagnostics | N/A | |
| Eryn Graham | Bluejay Diagnostics | N/A | |
| Nicholas DeGennaro | Vivos Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.69 |
Bone Biologics Corp Leadership Team
Elected by the shareholders, the Bone Biologics' board of directors comprises two types of representatives: Bone Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bone. The board's role is to monitor Bone Biologics' management team and ensure that shareholders' interests are well served. Bone Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bone Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shunichi Kuroda, CoFounder Board | ||
| Deina CPA, Chief Officer | ||
| Deina Walsh, Chief Officer | ||
| Jeffrey Frelick, CEO President |
Bone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bone Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.69 | ||||
| Current Valuation | (642.22 K) | ||||
| Shares Outstanding | 3.27 M | ||||
| Shares Owned By Insiders | 2.12 % | ||||
| Shares Owned By Institutions | 2.14 % | ||||
| Number Of Shares Shorted | 130.43 K | ||||
| Price To Earning | (15.45) X | ||||
| Price To Book | 0.77 X | ||||
| EBITDA | (4.22 M) |
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.